Wang Ying, Dong Chang-Qing, Peng Guang-Yin, Huang Hao-Yue, Yu Yun-Sheng, Ji Zhen-Chun, Shen Zhen-Ya
Department of Cardiovascular Surgery of the First Affiliated Hospital & Institute for Cardiovascular Science, Soochow University, Suzhou, Jiangsu, China.
Department of Cardiovascular Surgery of the First Affiliated Hospital & Institute for Cardiovascular Science, Soochow University, Suzhou, Jiangsu, China.
Mol Ther Nucleic Acids. 2019 Jun 7;16:284-294. doi: 10.1016/j.omtn.2019.02.021. Epub 2019 Feb 28.
Abnormal phenotypic switch, migration, and proliferation of vascular smooth muscle cells (VSMCs) are hallmarks for pathogenesis of thoracic aortic dissection (TAD). In the current study, we identified miR-134-5p as a critical regulator controlling human VSMC phenotypic switch and migration to investigate whether miR-134-5p affects human VSMC functions and development of TAD. Using miRNA microarray of aorta specimens from 12 TAD and 12 controls, we identified miR-134-5p, which was significantly downregulated in TAD tissues. With qPCR detection, we found that miR-134-5p was also evidently decreased in human AoSMCs. Ectopic expression of miR-134-5p obviously promoted VSMC differentiation and expression of contractile markers, such as α-SMA, SM22α, and MYH11. miR-134-5p potently inhibited PDGF-BB-induced VSMC phenotypic switch and migration. We further identified STAT5B and ITGB1 as downstream targets of miR-134-5p in human VSMCs and proved them to be mediators in VSMC phenotypic switch and progression of TAD. Finally, Ad-miR-134-5p obviously suppressed the aorta dilatation and vascular media degeneration by 39% in TAD mice after vascular injury induced by Ang II. Our findings revealed that miR-134-5p was a novel regulator in vascular remodeling and pathological progress of TAD via targeting STAT5B/ITGB1 expression. Targeting miR-134-5p or its downstream molecules in VSMCs might develop new avenues in clinical treatment of TAD.
血管平滑肌细胞(VSMC)的异常表型转换、迁移和增殖是胸主动脉夹层(TAD)发病机制的标志。在本研究中,我们鉴定出miR-134-5p是控制人类VSMC表型转换和迁移的关键调节因子,以研究miR-134-5p是否影响人类VSMC功能及TAD的发展。通过对12例TAD患者和12例对照者的主动脉标本进行miRNA微阵列分析,我们鉴定出miR-134-5p,其在TAD组织中显著下调。通过qPCR检测,我们发现miR-134-5p在人类主动脉平滑肌细胞(AoSMCs)中也明显降低。miR-134-5p的异位表达明显促进了VSMC分化及收缩标志物如α-平滑肌肌动蛋白(α-SMA)、平滑肌22α蛋白(SM22α)和肌球蛋白重链11(MYH11)的表达。miR-134-5p强烈抑制血小板衍生生长因子-BB(PDGF-BB)诱导的VSMC表型转换和迁移。我们进一步鉴定出信号转导和转录激活因子5B(STAT5B)和整合素β1(ITGB1)是人类VSMCs中miR-134-5p的下游靶点,并证明它们是VSMC表型转换和TAD进展的介质。最后,在血管紧张素II(Ang II)诱导血管损伤后的TAD小鼠中,腺病毒介导的miR-134-5p(Ad-miR-134-5p)明显抑制了主动脉扩张和血管中层退变达39%。我们的研究结果表明,miR-134-5p是通过靶向STAT5B/ITGB1表达而在TAD的血管重塑和病理进展中发挥作用的新型调节因子。靶向VSMCs中的miR-134-5p或其下游分子可能为TAD的临床治疗开辟新途径。